Pfizer kept at outperform by Bear Stearns

Pfizer Inc. was reiterated at outperform and given a $30 price target by Bear Stearns analyst John Boris. The company's 2006 cost-savings guidance increased to $2.5 billion from $2 billion and is not expecting top-line growth to reappear until 2009. The analyst projects flat sales through 2008 due to Lipitor and a lower contribution from new/pipeline products. Shares of the New York City pharmaceutical company were up 5 cents, or 0.18%, at $27.73. (NYSE: PFE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.